Unternehmen wird geladen
Keep exploring
The themes Nurix Therapeutics is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.48B $A+
EXELExelixis, Inc.17,3B $A+
JAZZJazz Pharmaceuticals plc15,9B $A
HALOHalozyme Therapeutics, Inc.11,6B $A+
TECHBIO-Techne Corp11,4B $A+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21. Okt. 2026CBGraded C, now B
MCKMckesson Corporation4. Nov. 2026BAGraded B, now A
CVSCVS Health Corp4. Nov. 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4. Nov. 2026BAGraded B, now A
BIIBBiogen Inc.28. Okt. 2026BAGraded B, now A
Womit das Unternehmen Geld verdient
- Collaboration revenue64 %
- License revenue36 %
Die Umsatzanteile sind Schätzungen für fiscal year ended 2025-11-30, high confidence und keine Zahlen aus einem eingereichten Bericht.
Konkurriert mit
Was es verkauft4
Bexobrutideg (NX-5948)
An experimental oral medicine designed to make cells remove Bruton tyrosine kinase, a protein involved in some blood cancers. It is being tested in patients with blood cancers, including chronic lymphocytic leukemia.
NX-1607
An experimental oral medicine that blocks CBL-B, a cell protein that restrains immune cells. It is being tested to help immune cells attack tumors.
Zelebrudomide (NX-2127)
An experimental oral medicine designed to remove Bruton tyrosine kinase and two proteins involved in immune-cell activity. Nurix discontinued further clinical development; some patients already receiving it may continue treatment.
NX-0479 / GS-6791
A partner-developed experimental medicine designed to degrade IRAK4, a protein involved in inflammation.
Wer es kauft4
- Gilead pays for research into drug candidates and may license candidates for further development.
- Sanofi pays for research into drug candidates and may license candidates for further development.
- Pfizer pays for research into drug candidates intended for attachment to antibodies and may license them for development.
- Roche licensed bexobrutideg and shares its development and United States commercial responsibilities with Nurix.
Worauf es steht, und was es umwerfen könnte
Wovon das Geschäft abhängt
- 1Nurix has no product-sale revenue and depends on collaboration payments, license payments, and outside financing to fund its work.
- 2It relies on contract manufacturers for drug ingredients and finished medicines used in clinical trials.
- 3It relies on outside organizations to conduct clinical trials and on pharmaceutical partners to develop or sell some licensed drug candidates.
Was schiefgehen könnte
- 1Nurix’s drug candidates are still being tested in people; trial results, safety findings, patient enrollment, or regulatory decisions could delay or end their development.
- 2Because Nurix has no approved medicines for sale, its income depends on partner payments and licensing events, which can vary in timing and may not recur.
- 3Problems with outside manufacturers or clinical-trial contractors could interrupt drug supply or delay trials.
Über Nurix Therapeutics, Inc.
Nurix develops experimental medicines designed to make cells remove disease-related proteins, rather than simply block them. Its discovery system uses machine learning and large chemical libraries to find starting points for drugs. Pharmaceutical partners pay for research and rights to drug candidates; Nurix also develops some candidates itself. It has no approved medicines for sale.
- Hauptsitz
- San Francisco, California
- Gegründet
- 2009 (founding year, medium confidence)
- Notiert an
- Nasdaq Global Select Market
- Geschäftsjahresende
- November 30
Gebaut aus den eigenen Einreichungen von Nurix Therapeutics, Inc. bei der US-Börsenaufsicht Securities and Exchange Commission (SEC). Die Zahlen sind wie berichtet, die Historie je Aktie auf die heutige Aktienbasis umgerechnet. Dies beschreibt ein Unternehmen — es ist keine Anlageberatung und keine Kauf- oder Verkaufsempfehlung.
